SSA
PSTX

Schonfeld Strategic Advisors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-289,179
Closed -$2.11M – 2621
2021
Q3 		$2.11M Buy
289,179
+34,576
+14% +$297K 0.02% 694
2021
Q2 		$2.55M Sell
254,603
-161,089
-39% -$1.44M 0.03% 641
2021
Q1 		$3.97M Buy
+415,692
New +$4.08M 0.05% 493
2020
Q4 		– Sell
-48,970
Closed -$434K – 1941
2020
Q3 		$434K Buy
+48,970
New +$557K 0.01% 963

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Schonfeld Strategic Advisors's PSTX Position: Q4 2021 in Review

Schonfeld Strategic Advisors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2021, closing a stake of 289,179 shares — an estimated $2.11M sold.

Schonfeld Strategic Advisors first reported a position in PSTX in Q3 2020 and held it in 4 quarters. The position peaked at $3.97M in Q1 2021. 66 funds tracked by Wall St. Rank hold PSTX as of Q4 2021.

  • Schonfeld Strategic Advisors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 289,179 Poseida Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2.11M.
  • Schonfeld Strategic Advisors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Poseida Therapeutics, Inc. Common Stock position peaked at $3.97M in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.